- Home
- FMY vs ATYR Comparison
FMY vs ATYR Comparison
Compare FMY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMY | ATYR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.9M | 49.2M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FMY | ATYR |
|---|---|---|
| Price | $11.06 | $0.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $2.86 |
| AVG Volume (30 Days) | 4.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.67 | $0.14 |
| 52 Week High | $12.36 | $1.11 |
Technical Indicators
Market Signals| Indicator | FMY | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 13.04 |
| Support Level | $10.71 | N/A |
| Resistance Level | $11.76 | $0.60 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 50.76 | 8.00 |
Price Performance
Historical ComparisonAbout FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).